Elixinol Wellness Limited

The company's financials show resilient growth, with revenue advancing from $3.84M in Q4 2022 to $6.77M in Q2 2024. Gross profit remained healthy with margins at 36% in Q2 2024 compared to -15% in Q4 2022. Operating income hit -$1.97M last quarter, sustaining a consistent -29% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$2.37M. Net income rose to -$2.76M, while earnings per share reached -$0.003. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.